Published on: May 9, 2012
New compounds have been found that disrupt the formation of amyloid—the clumps of protein in the brain thought to be important in causing the characteristic mental decline associated with Alzheimer’s disease.
The so-called “spin-labeled fluorene compounds” are an important new target for diagnosis and treatment of the disease, researchers say.
“We have found these small molecules to have significant beneficial effects on cultured neurons, from protecting against toxic compounds that form in neurons to reducing inflammatory factors,” says John C. Voss, professor of biochemistry and molecular medicine at the University of California, Davis School of Medicine and the principal investigator of the study.
“As a result, they have great potential as a therapeutic agent to prevent or delay injury in individuals in the earliest stages of Alzheimer’s disease, before significant damage to the brain occurs.”
Amyloid is an accumulation of proteins and peptides that are otherwise found naturally in the body. One component of amyloid—the amyloid beta (Aβ) peptide—is believed to be primarily responsible for destroying neurons in the brain.
Fluorene compounds—small three-ringed molecules—originally were developed as imaging agents to detect amyloid with PET imaging. In addition to being excellent for detecting amyloid, fluorenes bind and destabilize Aβ peptide and thereby reduce amyloid formation, according to previous findings in mice by Lee-Way Jin, another study author and associate professor in the MIND Institute and Department of Medical Pathology and Laboratory Medicine.
As reported in the journal PLoS One, the current research studied the effects of fluorene compounds by attaching a special molecule to make their activity evident using electron paramagnetic resonance (EPR) spectroscopy.
This technology allows researchers to observe very specific activities of molecules of interest because biological tissues do not emit signals detectable by EPR. Since Voss was interested in the activity of fluorenes, he added a nitroxide “spin label,” a chemical species with a unique signal that can be measured by EPR.
The group found that spin-labeled compounds disrupted Aβ peptide formation even more effectively than did non-labeled fluorenes. In addition, the antioxidant properties of the nitroxide, which scavenge reactive oxygen species known to damage neurons and increase inflammation, significantly contributed to the protective effects on neurons.
“The spin-labeled fluorenes demonstrated a number of extremely important qualities: They are excellent for detecting amyloid in imaging studies, they disrupt Aβ formation, and they reduce inflammation,” says Voss. “This makes them potentially useful in the areas of research, diagnostics and treatment of Alzheimer’s disease.”
Alzheimer’s disease is the most common form of dementia and affects some 5 million Americans. Current medications used to fight the disease usually have only small and temporary benefits, and commonly have many side effects.
A major obstacle in developing Alzheimer’s disease therapy is that most molecules will not cross the blood-brain barrier, so that potential treatments given orally or injected into the bloodstream cannot enter the brain where they are needed. Fluorene compounds are small molecules that have been shown to penetrate the brain well.
“We have brought together expertise from diverse fields to get to this point, and what was once a side interest has become a major focus,” says Voss. “We are very excited and hopeful that these unique compounds can become extremely important.”
Voss’ group next plans to study the safety of spin-labeled fluorene compounds as well as their efficacy for treating models of Alzheimer’s disease in small animals.
Researchers from the University of Pecs, Institute of Organic and Medicinal Chemistry in Hungary, and Miami University in Oxford, Ohio contributed to the study that was funded by grants from the National Institutes of Health and the Hungarian National Research Fund.
Source: Futurity (no longer available online)
Older people who report greater levels of social engagement have more robust gray matter in regions of the brain relevant in dementia, according to new research led by scientists at the University of Pittsburgh Graduate School of...
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.